Is bilirubin a marker of vascular disease and/or cancer and is it a potential therapeutic target?

Current Pharmaceutical Design

Volumn 17, Issue 33, 2011, Pages 3644-3655

  Breimer, Lars H ^a   Mikhailidis, Dimitri P ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Arterial disease; Bilirubin; Cancer; Genotypes; HMOX1; Reactive oxygen species; Stroke; UGT1A1

Indexed keywords

BILIRUBIN; CARBON MONOXIDE; CLOPIDOGREL; CORTICOSTEROID; GLUCURONOSYLTRANSFERASE 1A1; HEME OXYGENASE 1; HEME OXYGENASE 2; IRINOTECAN; LIPOXIN; NITRIC OXIDE DONOR; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTERY DISEASE; BILIRUBIN BLOOD LEVEL; BRAIN ISCHEMIA; CANCER PREVENTION; CARDIOVASCULAR FUNCTION; CAROTID ARTERY DISEASE; CATALYSIS; CELL PROTECTION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE MARKER; DRUG EFFICACY; FOLLOW UP; GENE LOCUS; GENETIC POLYMORPHISM; GENETICS; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IN VIVO STUDY; INTESTINE FLORA; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY MEDULLA; LIPOPHILICITY; LUNG CANCER; LUNG DISEASE; MORTALITY; NONHUMAN; PEDIATRICS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SEX DIFFERENCE; VASCULAR DISEASE;

EID: 82055170490     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798220927     Document Type: Review

References (118)

1. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genetics 2004; 38: 445-76.
2. Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Molec. Carcinogen 1990; 3: 188-97.
3. Breimer LH. Repair of DNA damage induced by reactive oxygen species. Free Radic Res Commun 1991; 14: 159-71.
4. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA Repair Genes. Science 2001; 291: 1284-9.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
6. Alabanes D. Vitamin supplements and cancer prevention: where do randomized controlled trials stand? J Natl Cancer Inst 2009; 101: 2-4.
7. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and metaanalysis. JAMA 2007; 297: 842-57.
8. Kuller LH. A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arterioscler Thromb Vasc Biol 2001; 21: 1253.
9. [Nelson Textbook of Pediatrics: 18th Edition & E-dition. Kliegman R, Behrman RE, Jenson HB, Stanton BMD (eds). WB Saunders Co, 2009. http://www.nelsonpediatrics.com/
10. Breimer LH. Does bilirubin act as a free radical quencher of clinical significance in neonates and children? J Ped Biochem 2010; 1: 29-37
11. Stocker R, Ames BN. Potential role of conjugated bilirubin and copper in the metabolism of lipid peroxides in bile. Proc Natl Acad Sci USA 1987; 84: 8130-4.
12. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994; 40: 18-23.
13. Breimer LH, Spyropolous KA, Winder AF, Mikhailidis DP, Hamilton G. Is bilirubin protective against coronary artery disease? Clin Chem 1994; 40: 1987-8.
14. Ohnaka K, Kono S. Bilirubin, cardiovascular diseases and cancer: epidemiological perspectives. Expert Rev Endocrinol Metab 2010; 5: 891-904.
15. [Simonsson P, Mårtensson A, Rustad P. Nya gemensamma referensvärden för klinisk kemi. Bättre bas för klinisk bedömning och samarbete [New common reference intervals for clinical chemistry in the Nordic countries. A better basis for clinical assessment and cooperation]. Läkartidningen 2004; 101: 901-5. [in Swedish, with English summary].
16. Manolio TA, Burke GL, Savage PJ, et al. Sex- and Race-Related Differences in Liver-Associated Serum Chemistry Tests in Young Adults in the CARDIA Study. Clin Chem 1992; 38: 1853-9.
17. "Tietz Textbook of Clinical Chemistry". Burtis CA & Ashwood ER, eds. 3rd edition, 1999. WB Saunders & Co.
18. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995; 41: 1504-8.
19. Pocock SJ, Ashby D, Shaper AG, Walker M, Broughton PMG. Diurnal variations in serum biochemical and haematological measurements. J Clin Pathol 1989; 42: 172-9.
20. Madhavan M, Wattingey WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis 1997; 131: 107-13.
21. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999; 12: 673-81.
22. Ganotakis ES, Vrentzos GE, Gazi IF, Papadakis JA, Jagroop A, Paraskevas KI, Nair DR, Mikhailidis DP. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo 2007; 21: 685-94.
23. Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40, 827-35.
24. Ohnaka K, Kono S, Inoguchi T, et al. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res. Clin. Pract 2010; 88, 103-10.
25. Breimer LH, Mikhailidis DP. Could carbon monoxide and bilirubin be friends as well as foes of the body? Scand J Clin Lab Invest 2010; 70(1): 1-5.
26. Endler G, Hamwi A, Sunder-Plassmann R, et al. Is Low Serum Bilirubin an Independent Risk Factor for Coronary Artery Disease in Men but Not in Women? Clin Chem 2003; 49: 1201-4.
27. Ryter SW, Alam J, Choi AMK. Heme oxygenase-1/Carbon Monoxide: From basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650.
28. Gustafsson BE, Lanke LS. Bilirubin and urobilins in germfree, exgermfree, and conventional rats. J Exp Med 1960; 112: 975-81.
29. Fevery, J, Bilirubin in clinical practice: a review. Liver Int 2008; 28: 592-605.
30. Leung JW, Liu LY, Leung PS, Chan RC, Inciardi JF, Cheng AF. Expression of bacterial beta-glucuronidase in human bile: an in vitro study. Gastrointest Endosc 2001; 54: 346-50.
31. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1: 6-14.
32. Vitek L, FMajer F, Muchova L, et al. Identification of bilirubin reduction products formed by Clostridium perfringens isolated from human neonatal fecal flora. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 833: 149-57.
33. Vitek L, Kotal P, Jirsa M, Malina J, Cerna M, Chmelar D, Fevery J. Intestinal colonization leading to fecal urobilinoid excretion may play a role in the pathogenesis of neonatal jaundice. J Pediatr Gastroenterol Nutr 2000; 30: 294-8.
34. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010. 464: 59-65.
35. Djousse L, Levy D, Cupples LA, Evans JC, D0Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001; 87: 1196-200.
36. Temme EH, Zhang J, Schouten EG, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 2001; 12: 887-94.
37. Troughton JA, Woodside JV, Young IS, et al. Evans Alun, on behalf of the PRIME Study Group. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 2007; 14: 79-84.
38. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med 2003; 228: 568-71.
39. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16: 250-55.
40. Hunt SC, Wu LL, Hopkins PN, Williams RR. Evidence for a major gene elevating serum bilirubin concentration in Utah pedigrees. Arterioscler Thromb Vasc Biol 1996; 16: 912-7.
41. Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem 2003; 49: 1180-81.
42. Ekblom K, Marklund SL, Jansson JH, et al. Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective nested case-referent setting. Circ Cardiovasc Genet 2010; 3: 340-7.
43. Fulks M, Stout RL, Dolan VF. Mortality associated with bilirubin levels in insurance applicants. J Insur Med 2009; 41: 49-53.
44. Breimer LH. Bilirubin and cardiovascular disease. J Insur Med 2009; 41: 230-31.
45. Breimer LH, Mikhailidis DP. Bilirubin and peripheral arterial disease: 15 years later. Expert Opin Ther Targets 2009; 13: 139-40.
46. Rantner B, Kollertis B, Anderwald-Stadler M, et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 2008; 54: 851-7.
47. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease. Arterioscl Thromb Vascul Biol 2008; 28: 166-72.
48. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009; 40: 3422-7.
49. Ekblom K, Marklund SL, Johansson L, et al Bilirubin and UGT1A1*28, are not associated with lower risk for ischemic stroke in a prospective nested case-referent setting. Cerebrovasc Dis 2010; 30: 590-6.
50. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008; 121: 781-8.
51. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke 2001; 32: 580-3.
52. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler. Thromb Vasc Biol. 25: 1038-44.
53. Yang XF, Chen YZ, Su JL, Wang FY, Wang LX. Relationship between serum bilirubin and carotid atherosclerosis in hypertensive patients. Inter Med 2009; 48: 1595-9.
54. Erdogan D, Gullu H, Yildirim E, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006; 184: 431-7.
55. Vitek L, Novotny L, Sperl M, Holaj R, Spacil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc. Dis 2006; 21: 408-14.
56. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-9.
57. Chin J H, on behalf of the Progressive REnal disease and MedicalInformatics and gEnomics Research (PREMIER) members. The Mildly Elevated Serum Bilirubin Level is Negatively Associated with the Incidence of End Stage Renal Disease in Patients with IgA Nephropathy. J Korean Med Sci 2009; 24 (Suppl 1): S22-9.
58. Gullu H, Erdogan D, Tok D, et al. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol 2005; 25: 2289-94.
59. Horsfall LJ, Rait G, Walters K, et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011; 305: 691-7.
60. Benaron DA, Bowen FW. Variation of initial serum bilirubin rise in newborn infants with type of illness. Lancet 1991; 338: 78-81.
61. Dani C, Martelli E, Bertini G, et al. Plasma bilirubin level and oxidative stress in preterm Infants. Arch Dis Child Fetal Neonatal Ed 2003; 88: F119-23.
62. Bhuiyan AR, Srinivasan SR, Chen W, Sultana A, Berenson GS. Association of serum bilirubin with pulsatile arterial function in asymptomatic young adults: the Bogalusa Heart Study. Metabolism 2008; 57: 612-6.
63. Kumar V, Cotran RS, Robbins SL. Robbins Basic Pathology. 7th ed. Philadelphia: Saunders; 2003.
64. Fan C, Zwacka RM, Engelhardt JF. Therapeutic approaches for ischemia/reperfusion injury in the liver. J Mol Med 1999; 77: 577-92.
65. Demirogullari B, Ekingen G, Guz G, et al. A comparative study of the effects of hemin and bilirubin on bilateral renal ischemia reperfusion injury. Nephron Exp Nephrol 2006; 103: e1-e5.
66. Öllinger R, Wang HJ, Yamashita K, et al. Therapeutic Applications of Bilirubin and Biliverdin in Transplantation. Antioxid. Redox Signal 2007; 9: 2175-85.
67. Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R. Novel Aspects of Oxidative Stress in Cardiovascular Diseases. Circ J 2009; 73: 201-7.
68. Sentman M-L, Brännström T, Westerlund S, Laukkanen, MO, Ylä-Herttuala S, Basu, S, Marklund SL. Extracellular-superoxide dismutase deficiency and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol 2001; 21: 1477-82.
69. Sanoff HK, Sargent DJ, Campbell ME, et al. Pitot, and Richard M. Goldberg. Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741. J Clin Oncol 2008; 26: 5721-7.
70. Sjostrand T. Endogenous production of carbon monoxide in man under normal and pathophysiological conditions. Scand J Clin Lab Invest 1949; 1: 201-14.
71. Sjostrand T. The formation of carbon monoxide by the decomposition of hemoglobin in vivo. Acta Physiol Scand 1952: 26: 338-44.
72. Foresti R, Green CJ, Motterlini R. Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. Biochem Soc Symp. 2004; 71: 177-92.
73. Motterlini R, Mann BE, Foresti R. Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin Investig Drugs. 2005; 14: 1305-18.
74. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 2004; 113: 1776-82.
75. Maghzal GH, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in cellular antioxidant protection by biliverdin. J Biol Chem 2009; 284(43): 29251-9.
76. Oberle S, Abate A, Grosser N, et al. Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med 2003; 228: 529-34.
77. Serhan CN, Takano T, Maddox JF. Aspirin-triggered 15-epilipoxin A4 and stable analogs on lipoxin A4 are potent inhibitors of acute inflammation: receptors and pathways. Adv Exp Med Biol 1999; 447: 133-49.
78. Weid P-Y, Hollenberg MD, Fiorucci S, Wallace JL. Aspirin- Triggered, Cyclooxygenase-2-Dependent Lipoxin Synthesis Modulates Vascular Tone. Circulation 2004; 110: 1320-5.
79. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Villela CG, Fierro IM. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol 2005; 289: C557-63.
80. Foresti R, Hammad J, Clark JE, et al. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br J Pharmacol 2004; 142: 453-60.
81. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005; 288: F778-84.
82. Kirkby K, Baylis C, Agarwal A, Croker B, Archer L, Adin C. Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am J Physiol Renal Physiol 2007; 292: 888-94.
83. Ceran C, Sonmez K, Turkyllmaz Z, et al. Effect of bilirubin in isch- emia/reperfusion injury on rat small intestine. J Pediatr Surg 2001; 36: 1764-7.
84. Kato Y, Shimazu M, Kondo M, et al. Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase- 1 preconditioning. Hepatology 2003; 38: 364-73.
85. Wang H, Lee SS, Dell'Agnello C, et al. Bilirubin can induce tolerance to islet allografts. Endocrinology 2006; 147: 762-8.
86. Sato K, Balla J, Otterbein L, et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol 2001; 166: 4185-94.
87. Attuwaybi BO, Kozar RA, Moore-Olufemi SD, et al. Heme oxygenase-1 induction by hemin protects against gut ischemia/reperfusion injury. J Surg Res 2004; 118(1): 53-7.
88. Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004; 37: 2064-71.
89. Gueler F, Park JK, Rong S, et al. Statins attenuate ischemiareperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 2007; 170: 1192-9.
90. Muchova L, Wong RJ, Hsu M, et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 2007; 85: 800-10.
91. Díaz-Gil JJ, Gavilanes JG, Sánchez G, García-Canero R, García-Segura JM, Santamaría L. Identification of a liver growth factor as an albumin-bilirubin complex. Biochem. J 1987; 234: 443-8.
92. Condezo-Hoyos L, Abderrahim F, Conde MV, et al. Antioxidant activity of liver growth factor, a bilirubin covalently bound to albumin. Free Rad Biol Med 2009; 46: 656-62.
93. Lin JP, Vitek L, Schwertner HA. Serum Bilirubin and Genes Controlling Bilirubin Concentrations as Biomarkers for Cardiovascular Disease. Clin Chem 2010; 56(10): 1535-43.
94. Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 2009; 27: 2419-21.
95. Olsson R, Bliding A, Jagenburg R, et al. Gilbert's syndrome-does it exist? A study of the prevalence of symptoms in Gilbert's syndrome. Acta Med Scand 1988; 224: 485-90.
96. Yusoff S, Van Rostenberghe H, Yusoff NM, et al. Frequencies of A(TA)7TAA, G71R, and G493R mutations of the UGT1A1 gene in the Malaysian population. Biol Neonate 2006; 89: 171-6.
97. Vitek L, Jirsa M, Brodanova M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002; 160: 449-56.
98. Gajdos V, Petit FM, Perret C, et al. Further Evidence That the UGT1A1*28 allele is not associated with coronary heart disease: the ECTIM study. Clin Chem 2006; 52(12): 2313-4
99. Lingenhel A, Kollerits B, Schwaiger JP, et al. Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease. Exp Gerontol 2008; 43: 1102-7.
100. Lin JP, O'Donnell CJ, Schwaiger JP, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006; 114: 1476-81.
101. Kronenberg F. Association of bilirubin with cardiovascular outcomes: more hype than substance? Circ Cardiovasc Genet 2010; 3: 308-10.
102. Chen YH, Lin SJ, Lin MW, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum. Genet 2002; 111: 1-8.
103. Kaneda H, Ohno M, Taguchi J, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler. Thromb. Vasc. Biol 2002; 22: 1680-5.
104. Dick P, Schillinger M, Minar E, et al. Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease. Eur J Clin Invest 2005; 35(12): 731-7.
105. Theobald H, Bygren LO, Carstensen J, Engfeldt P. A moderate intake of wine is associated with reduced total mortality and reduced mortality from cardiovascular disease. J Stud Alcohol 2000; 61: 652-6.
106. Shaper AG. Mortality and alcohol consumption. Non-drinkers shouldn't be used as a baseline. BMJ 1995; 310: 325.
107. Ekblom K, Marklund SL, Jansson JH, Hallmans G, Weinehall L, Hultdin J. Iron stores and HFE genotypes are not related to increased risk of first-time myocardial infarction. A prospective nested case-referent study. Accepted for publication in Int J Cardiol 2010; 141: 132-40.
108. Ekblom K, Hultdin J, Stegmayr B, et al. Iron stores and HFE genotypes are not related to increased risk of ischemic stroke. A prospective nested casereferent study. Cerebrovasc Dis 2007; 24(5): 405-11.
109. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radicalcaused aging and cancer: A hypothesis. Proc. NatL Acad. Sci. USA 1981; 78(11): 6858-62.
110. Levine W, Dyer AR, Shekelle RB, et al. Serum uric acid and 11.5- year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42: 257-67.
111. Freedman DS, Williamson DF, Gunter EW, Beyers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic follow-up study. Am J Epidemiol 1995; 141: 637-44.
112. Liese AD, Hense HW, Lowel H, et al. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. Epidemiology 1999; 10: 391-7.
113. Tomita M, Mizuno S, Yamanaka H et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10: 403-9.
114. Mazza A, Pessina AC, Pavei A, et al. Predictors of stroke mortality in elderly people from the general population. The cardiovascular study in elderly. Eur J Epidemiol 2001; 17: 1097-104.
115. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.
116. Petersson B, Trell E. Raised serum urate concentration as a risk factor for premature mortality in middle aged men: relation to death from cancer. BMJ 1983; 287: 7-9.
117. Strasak AM, Rapp K, Hilbe W, et al. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Ann Oncol 2007; 18(11): 1893-7.
118. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med 1999; 131(1): 7-13.